172 related articles for article (PubMed ID: 9840702)
1. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis.
Nakao T; Matsumoto H; Okada T; Han M; Hidaka H; Yoshino M; Shino T; Yamada C; Nagaoka Y
Intern Med; 1998 Oct; 37(10):826-30. PubMed ID: 9840702
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
Schmidt G; Stamminger G; Daniel A; Gross J; Syllm-Rapoport I; Lun A; Zoellner K
Biomed Biochim Acta; 1990; 49(2-3):S275-9. PubMed ID: 2386517
[TBL] [Abstract][Full Text] [Related]
3. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
4. Correlation between glycated hemoglobin and mean plasma glucose in hemodialysis patients.
Israel E; Geara A; Maarouf O; Ayoub I; Abi Rached J; Rizk S; Staynberg N; Samarneh M; El-Sayegh S
Int Urol Nephrol; 2011 Dec; 43(4):1149-53. PubMed ID: 20658265
[TBL] [Abstract][Full Text] [Related]
5. Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.
Pradella M; Cavill I; d'Onofrio G
Clin Lab Haematol; 1996 Dec; 18 Suppl 1():35-7. PubMed ID: 9054717
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
7. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c).
Uzu T; Hatta T; Deji N; Izumiya T; Ueda H; Miyazawa I; Kanasaki M; Isshiki K; Nishio T; Arimura T
Ther Apher Dial; 2009 Apr; 13(2):89-94. PubMed ID: 19379146
[TBL] [Abstract][Full Text] [Related]
8. Is erythropoietin a survival factor for red blood cells?
Polenakovic M; Sikole A
J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease.
Maruyama T; Takashima H; Oguma H; Nakamura Y; Ohno M; Utsunomiya K; Furukawa T; Tei R; Abe M
Diabetes Technol Ther; 2019 Dec; 21(12):713-720. PubMed ID: 31385724
[No Abstract] [Full Text] [Related]
12. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K; Soma M
Int J Artif Organs; 2011 Jan; 34(1):16-25. PubMed ID: 21298620
[TBL] [Abstract][Full Text] [Related]
13. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin.
Debska-Slizień A; Owczarzak A; Kunicka D; Lysiak-Szydłowska W; Rutkowski B
Int J Artif Organs; 2003 Jan; 26(1):33-8. PubMed ID: 12602467
[TBL] [Abstract][Full Text] [Related]
14. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
Moreno F; Aracil FJ; Pérez R; Valderrábano F
Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
[TBL] [Abstract][Full Text] [Related]
15. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
16. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
17. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.
Ross RP; McCrea JB; Besarab A
ASAIO J; 1994; 40(3):M880-5. PubMed ID: 8555638
[TBL] [Abstract][Full Text] [Related]
19. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment.
Zachée P; Ferrant A; Daelemans R; Coolen L; Goossens W; Lins RL; Couttenye M; De Broe ME; Boogaerts MA
Nephron; 1993; 65(2):288-93. PubMed ID: 8247195
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
